不同剂量瑞舒伐他汀对AMI患者血浆SAA、Hs-CRP、N-pro-BNP水平的影响

目的观察不同剂量瑞舒伐他汀对急性心肌梗死（acute myocardial infarction,AMI）患者血浆血清淀粉样蛋白A（SAA）、超敏C反应蛋白（hs-CRP）、N末端B型脑钠肽前体（NT-pro-BNP）水平的影响。方法 56例急性心肌梗死患者经PCI后,接受常规治疗,随机分为两组：A组（n=28）给予瑞舒伐他汀（10mg/d）,B组（n=28）强化剂量（20mg/d）治疗,两组疗程均为3个月,观察心血管事件发生情况。并设健康对照组（n=24）。结果与对照组相比,A、B两组血清hs-CRP、SAA、NT-pro-BNP水平显著升高（P〈0.05）;治疗后1、2周A、B两组血清hsCRP、SAA、NT-pro-BNP水平均明显下降,差异有统计学意义（P〈0.05）;且B组下降幅度更大,差异有统计学意义（P〈0.05）。随访3个月B组总心血管事件发生率明显低于A组,差异有统计学意义（P〈0.05）。结论 PCI术后给予强化瑞舒伐他汀治疗短期即可显著降低血清炎性因子,且疗效优于常规治疗剂量,有利于AMI患者的恢复。

Influence of different doses of rosuvastati on levels of serum high sensitivity C-reactive protein serum Amyloid A and N-terminal pro-brain natriuretic peptide in the patients with acute myocardial infarction

Objective To observe the influence of the different doses of rosuvastati on serum hs-CRP, SAA and NT- pro-BNP in the patients with acute myocardial Infarction. Methods Fifty-six cases of acute myocardial infarction patients after PCI, accepted conventional treatment, they were randomly divided into two groups： group A （n = 28） was given rosuvastati （10 mg/d）, and group B （n = 28） strengthen the dose （20 mg/d） treated, two groups of treatment were for 3 months, the cardiovascular events occur was observed. And 24 healthy subjects were selected as the control group. Results Before intervention, the serum hs-CRP, SAA and NT-pro-BNP levels in group A and group B were higher than that in control group （P 〈 0.05）. After treatment of one, two weeks, the serum hs-CRP, SAA and NT-pro-BNP levels in group A and group B were decreased, the difference was statistically significant （P 〈 0.05）. and the decline was even greater in group B, the difference was statistically significant （P 〈 0.05）. Follow-up of 3 months B group always the risk of cardiovascular events was significantly lower than the group A, the difference was statistically significant （P 〈 0.05）. Conclusion PCI postoperative to strengthen rosuvastati therapy short-term can significantly reduce serum inflammatory factor, and the curative effect is better than the conventional therapeutic dose, which is beneficial to the recovery of patients with AMI.